Raymond James Downgrades PTC Therapeutics to Underperform
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has downgraded PTC Therapeutics (NASDAQ:PTCT) from Outperform to Underperform.
September 15, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics has been downgraded by Raymond James from Outperform to Underperform.
The downgrade by Raymond James, a major financial services firm, could negatively impact investor sentiment towards PTC Therapeutics. This could potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100